Amiselimod exhibits favourable safety in healthy individuals
        27 Jan 2021
    byAudrey Abella 
        Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.